CA3227603A1 - Pparg inverse agonists and uses thereof - Google Patents
Pparg inverse agonists and uses thereof Download PDFInfo
- Publication number
- CA3227603A1 CA3227603A1 CA3227603A CA3227603A CA3227603A1 CA 3227603 A1 CA3227603 A1 CA 3227603A1 CA 3227603 A CA3227603 A CA 3227603A CA 3227603 A CA3227603 A CA 3227603A CA 3227603 A1 CA3227603 A1 CA 3227603A1
- Authority
- CA
- Canada
- Prior art keywords
- halo
- compound
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229861P | 2021-08-05 | 2021-08-05 | |
| US63/229,861 | 2021-08-05 | ||
| PCT/US2022/039385 WO2023014861A1 (en) | 2021-08-05 | 2022-08-04 | Pparg inverse agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227603A1 true CA3227603A1 (en) | 2023-02-09 |
Family
ID=83149096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227603A Pending CA3227603A1 (en) | 2021-08-05 | 2022-08-04 | Pparg inverse agonists and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250122169A1 (https=) |
| EP (1) | EP4380928B1 (https=) |
| JP (1) | JP2024529534A (https=) |
| AU (1) | AU2022323260A1 (https=) |
| CA (1) | CA3227603A1 (https=) |
| WO (1) | WO2023014861A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117616012A (zh) * | 2021-03-02 | 2024-02-27 | 弗拉雷治疗公司 | Pparg反向激动剂及其用途 |
| EP4490147A1 (en) * | 2022-03-08 | 2025-01-15 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| CA3254026A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Inverse PPARG agonists and their uses |
| US20230382910A1 (en) * | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2024211969A1 (en) * | 2023-04-12 | 2024-10-17 | Setonix Pharmaceuticals Pty Ltd | Pparg modulators |
| WO2024221455A1 (en) * | 2023-04-28 | 2024-10-31 | Flare Therapeutics, Inc. | Crystalline forms of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2496234A1 (en) * | 2009-11-07 | 2012-09-12 | Merck Patent GmbH | Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors |
| WO2017061957A1 (en) * | 2015-10-09 | 2017-04-13 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| CN107522657B (zh) * | 2017-09-28 | 2020-06-26 | 上海中医药大学 | 一种具有ppar多重激动活性的化合物及其制备方法和应用 |
| CN117616012A (zh) * | 2021-03-02 | 2024-02-27 | 弗拉雷治疗公司 | Pparg反向激动剂及其用途 |
-
2022
- 2022-08-04 CA CA3227603A patent/CA3227603A1/en active Pending
- 2022-08-04 AU AU2022323260A patent/AU2022323260A1/en active Pending
- 2022-08-04 JP JP2024506646A patent/JP2024529534A/ja active Pending
- 2022-08-04 WO PCT/US2022/039385 patent/WO2023014861A1/en not_active Ceased
- 2022-08-04 EP EP22761764.4A patent/EP4380928B1/en active Active
- 2022-08-04 US US18/294,768 patent/US20250122169A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4380928A1 (en) | 2024-06-12 |
| US20250122169A1 (en) | 2025-04-17 |
| WO2023014861A1 (en) | 2023-02-09 |
| EP4380928B1 (en) | 2025-10-01 |
| AU2022323260A1 (en) | 2024-02-15 |
| JP2024529534A (ja) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3227603A1 (en) | Pparg inverse agonists and uses thereof | |
| AU2015369712B2 (en) | Mutant IDH1 inhibitors useful for treating cancer | |
| JP7853310B2 (ja) | Ｐｐａｒｇ逆アゴニストおよびその使用 | |
| US11820747B2 (en) | PPARG inverse agonists and uses thereof | |
| CA2923269C (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| US20250186425A1 (en) | Pparg inverse agonists and uses thereof | |
| WO2020046975A1 (en) | Methods of treating neurodegenerative diseases | |
| WO2023172846A1 (en) | Pparg inverse agonists and uses thereof | |
| JP2011508758A (ja) | Ｎ−フェニルイミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、これらの調製およびこれらの治療用途 | |
| JP2004538313A (ja) | ヘテロアリールへテロアルキルアミン誘導体および一酸化窒素シンターゼの阻害剤としてのそれらの使用 | |
| HK40118248A (en) | Pparg inverse agonists and uses thereof | |
| HK40118248B (en) | Pparg inverse agonists and uses thereof | |
| NZ721993B2 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| NZ721993A (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250728 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250728 |